Drugs Made In America Acquisition Corp. (DMAA) reported a net income of $5.9 million for the fiscal year ending December 31, 2025, primarily driven by interest income of $8.8 million from cash and investments held in a trust account. This figure represents a significant recovery from a net loss of $279,845 in the previous fiscal year, which was attributed to general and administrative expenses. The company has not yet engaged in any operational activities or generated revenue from business operations, as it remains focused on identifying potential acquisition targets.
The company successfully completed its initial public offering (IPO) on January 29, 2025, raising $200 million by selling 20 million units at $10 each. Following the IPO, DMAA also executed a private placement of 400,000 units, generating an additional $4 million. The underwriters exercised their over-allotment option, resulting in an additional $30 million in gross proceeds. As of February 18, 2025, a total of $231.15 million from these transactions was placed in a trust account for the benefit of public shareholders, which will be utilized for future business combinations.
In terms of operational developments, DMAA has undergone significant management changes. On October 8, 2025, Glenn Worman resigned as Chief Financial Officer, and Saleem Elmasri was appointed to the position on November 17, 2025. Additionally, Lynn Stockwell, the former CEO, resigned on February 28, 2026, and Roger Bendelac was appointed as her successor. These changes come amid ongoing efforts to secure a business combination, with the company currently evaluating a potential acquisition involving Power Analytics Global Corporation, a technology platform focused on artificial intelligence and cybersecurity.
DMAA's current financial position indicates a working capital deficit of $363,981 as of December 31, 2025, with cash reserves of only $6,137. The company has acknowledged the need for additional financing to cover operational costs and pursue its acquisition strategy. To address this, DMAA has entered into an interim convertible note agreement for $100,000, with plans for a larger financing commitment of $500,000. The company is also exploring various avenues for potential business combinations, particularly in sectors that align with its management team's expertise.
Looking ahead, DMAA has a maximum of 15 months from the IPO to complete its initial business combination, with the possibility of extending this period by up to six months. The company has indicated that it may seek shareholder approval for further extensions if necessary. However, if a business combination is not completed within the designated timeframe, DMAA will be required to liquidate and redeem public shares at a pro-rata amount from the trust account. The company remains focused on identifying suitable acquisition targets that can leverage its management team's experience and drive growth in the pharmaceutical and technology sectors.
About Drugs Made In America Acquisition Corp.
A special purpose acquisition company (SPAC) incorporated in the Cayman Islands, Drugs Made in America Acquisition Corp. aims to identify and acquire a leading pharmaceutical business in the United States. Its focus is on building a fully integrated, domestic drug manufacturing platform to enhance supply chain resilience, reduce reliance on foreign sources, and address drug shortages. The company leverages industry expertise, strategic acquisitions, and public market access to create value in the pharmaceutical sector.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.